- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
FDA approves Vectical for treatment of mild-to-moderate psoriasis
National report - The Food and Drug Administration has approved Vectical (Galderma), an ointment containing calcitriol, for the treatment of mild-to-moderate psoriasis, according to WebMD.
National report
- The Food and Drug Administration has approved Vectical (Galderma), an ointment containing calcitriol, for the treatment of mild-to-moderate psoriasis, according to WebMD.
Vectical is the first FDA-appoved ointment containing the active form of vitamin D3, and is approved for use only in adults 18 and older. Studies in children are underway, WebMD reports.
The ointment is safe during one year of continuous use, however, side effects include changes in the way the body uses calcium. Therefore, people with known metabolic calcium disturbances, and those taking drugs that affect calcium levels should use Vectical with caution, according to WebMD.
